Home Cart Sign in  
Chemical Structure| 2289691-01-4 Chemical Structure| 2289691-01-4

Structure of MYCi975
CAS No.: 2289691-01-4

Chemical Structure| 2289691-01-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MYCi975 improved analog of MYCi361 which is a MYC inhibitor. It showed better tolerability compared with MYCi361.

Synonyms: NUCC-0200975

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MYCi975

CAS No. :2289691-01-4
Formula : C25H16Cl2F6N2O2
M.W : 561.30
SMILES Code : OC1=C(C2=CC(C(F)(F)F)=NN2C)C=CC(OCC3=CC=C(Cl)C=C3)=C1C4=CC=C(Cl)C(C(F)(F)F)=C4
Synonyms :
NUCC-0200975
MDL No. :MFCD32263413
InChI Key :VSDFDVBYONIJLD-UHFFFAOYSA-N
Pubchem ID :139600320

Safety of MYCi975

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MYCi975

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
P493-6 cells 6 μM 24 hours To assess the effect of MYCi975 on MYC-dependent gene expression, results showed that MYCi975 significantly suppressed the expression of MYC target genes. PMC6939458
PC3 cells 6 μM 1 hour To assess the effect of MYCi975 on MYC/MAX interaction, results showed that MYCi975 significantly disrupted the formation of MYC/MAX complex. PMC6939458
HN12 cells 5 μM 48 hours To evaluate the effect of MYCi975 on cellular glutamine consumption, results showed that MYCi975 significantly inhibited glutamine consumption PMC11444885
HN6 cells 5 μM 48 hours To evaluate the effect of MYCi975 on cellular glutamine consumption, results showed that MYCi975 significantly inhibited glutamine consumption PMC11444885
MCF7 breast cancer cells 10 μM 48 hours MYCi975 treatment reduced FOXA1 occupancy at co-occurring ERα binding sites. PMC9045724
P493-6 lymphoma cells 6 μM 24 hours MYCi975 treatment affected gene expression related to DNA metabolic process, DNA replication, and cell cycle pathways. PMC9045724
PC3 prostate cancer cells 8 μM 24 hours MYCi975 treatment affected gene expression related to DNA metabolic process, DNA replication, and cell cycle pathways. PMC9045724
22Rv1 prostate cancer cells 10 μM 1, 4, 8, 24, 48 hours RNA-seq demonstrated that MYCi975 treatment had a significant effect on a core set of DNA synthesis and cell cycle progression genes. PMC9045724
H929 cells 5 μM 48 hours Evaluate the effect of MYCi975 on H929 cells, showing MYCi975 enhanced T cell-mediated killing of H929 cells PMC11250500
MM cell lines 6.4 μM (average EC50) 96 hours Evaluate the sensitivity of MM cell lines to MYCi975, showing most MM cell lines were sensitive to MYCi975 with MYC protein degradation PMC11250500

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MycCaP allograft model I.p. 100 mg/kg/day Once daily for 14 days To assess the inhibitory effect of MYCi975 on tumor growth, results showed that MYCi975 significantly inhibited tumor growth and increased tumor immune cell infiltration. PMC6939458
NSG mice Orthotopic buccal mucosal tumor model Intraperitoneal injection 100 mg/kg Once daily for 15 days To evaluate the antitumor efficacy of MYCi975 alone or in combination with CB-839, results showed that the combination therapy significantly suppressed tumor growth and lymph node metastasis PMC11444885
Nude mice 22Rv1 xenograft model Oral 100 mg/kg BID 5 days a week for 3 weeks MYCi975 (100 mg/kg BID) led to a significant inhibition of tumor growth without any adverse effect on mouse body weight. PMC9045724
NOD/SCID mice HNSCC PDX model Intraperitoneal injection 100 mg/kg Every 2 days for 6 weeks Investigate the effect of MYCi975 on HNSCC PDX model, including inhibition of tumor growth and overcoming cisplatin resistance. PMC10758066
BALB/c-nude female mice HN6 cell line-derived xenograft model Subcutaneous injection 100 mg/kg Every 2 days for 4 weeks MYCi975 significantly inhibited the growth of HN6 cell line-derived xenograft tumors. PMC9543056
BALB/c-nude female mice Cell line-derived xenograft model Subcutaneous injection 100 mg/kg Every 2 days for 4 weeks MYCi975 inhibited HNSCC growth and promoted CD8+ T cell infiltration. PMC9543056

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.91mL

1.78mL

0.89mL

17.82mL

3.56mL

1.78mL

References

 

Historical Records

Categories